DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Comparison of the Effect of Dorzolamide and Timolol on Optic Disk Blood Flow in Patients With Open Angle Glaucoma

Information source: Medical University of Vienna
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Glaucoma, Open-Angle

Intervention: Dorzolamide 2% (Drug); Timolol 0.5% (Drug)

Phase: Phase 2/Phase 3

Status: Completed

Sponsored by: Medical University of Vienna

Official(s) and/or principal investigator(s):
Hans G Eichler, MD, Prof., Principal Investigator, Affiliation: Medical University of Vienna

Summary

Glaucoma is one of the most common causes of blindness in the industrialized nations. For a long time glaucoma has been defined as a disease in which high intraocular pressure (IOP) leads to irreversible optic disk damage and concommitant visual field loss. However, recent investigations show that IOP is not necessarily an adequate measure of clinical severity or a predictor of clinical progression: about 20% of all eyes with high IOP do not develop visual field loss and some patients suffering from visual field loss due to optic disk damage have normal IOP. Hence, factors other than IOP are likely involved in the pathogenesis of glaucoma. The role of vascular factors in the pathogenesis of glaucoma has recently received much attention and optic nerve head hypoperfusion may play a critical role in the development of glaucoma. It may therefore be important for an optimal prevention of visual field defects in glaucoma that the topical antiglaucoma drugs used do not only reduce IOP but also stabilize or enhance the perfusion of the optic nerve head. Therefore, the aim of the present study is to compare the effect of a 3 months treatment with timolol or dorzolamide in patients with open angle glaucoma on optic disk blood flow.

Clinical Details

Official title: A Double-masked Comparison of the Effect of Dorzolamide and Timolol on Optic Disk Blood Flow in Patients With Open Angle Glaucoma

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science

Primary outcome:

Percent change over baseline after 3 months of treatment of optic disk blood flow measured with the Heidelberg Retina Flowmeter

Percent change over baseline after 3 months of treatment of fundus pulsation amplitude (FPA) in the optic disk as assessed with laser interferometry

Eligibility

Minimum age: 19 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Men and women older than 19 years

- Primary open angle glaucoma or ocular hypertension with IOP higher than 22 mmHg in at

least one eye

- Washout period for previous antiglaucoma treatment: two weeks for adrenergic

agonists, one week for parasympathomimetic agents Exclusion Criteria:

- Exfoliation glaucoma, pigmentary glaucoma

- History of acute angle closure

- Intraocular surgery or argon laser trabeculoplasty within the last 6 months

- Ocular inflammation or infection within the last 3 months

- Contact lenses

- Patients with bradycardia (heart rate less than 50 beats/min)

- Second or third degree heart block

- Asthma

- COPD

- Congestive Heart Failure

- Severe renal impairment (Creatinine clearance less than 1. 8 l/h

- History or hypersensitivity to one of the study drugs or drugs with similar chemical

structure

- History of non-IOP responder to beta-blockers or carbonic anhydrase inhibitors

- Pregnancy

Locations and Contacts

Department of Clinical Pharmacology, Medical University of Vienna, Vienna 1090, Austria
Additional Information

Starting date: May 1999
Last updated: October 7, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017